Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

24.86 +0.06 (+0.24%)
Official Closing Price Updated: 7:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants. 
Via The Motley Fool
3 Ultra-High-Yield Dividend Stocks That Could Realistically Double Your Money by 2030
There's no guarantee these stocks can generate 100% returns by 2030. But they have a clear path to make it happen. 
Via The Motley Fool
Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?
What's good for Wood and Ark Invest might not be good for other investors. 
Via The Motley Fool
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The price could be right for these three biopharma stocks. 
Via The Motley Fool
Study Questions Serious Flaws in $35 Million Antidepressant Research
CCHR says millions of taxpayer dollars are wasted on psychotropic drug research later found to be flawed and harmful to consumersLOS ANGELES - March 22, 2024 - PRLog -- Researchers have reanalyzed data... 
Via PRLog
Topics Fraud
Exposures Legal Product Safety
Pfizer Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Is Pfizer the Best Dividend Stock for You?
Pfizer's stock is cheap, and it pays an incredibly high yield right now. 
Via The Motley Fool
7 Stocks That Will Make Your Friends Green with Envy
Discover stocks set to dazzle the market with innovative business models and disruptive technologies. Dive in for potential outperformance. 
Via InvestorPlace
A Bull Market Is Here: 2 Magnificent Stocks Down 30% or More to Buy Right Now
These stocks share several things in common. 
Via The Motley Fool
2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?
After a lousy year of declining prices, these stocks offer yields of 4.7% and 6.1% at recent prices. 
Via The Motley Fool
Will Pfizer Be a Trillion-Dollar Stock by 2035?
A market cap of $1 trillion for Pfizer over the next 11 or so years? Possible, but not probable. 
Via The Motley Fool
7 High-Value Stocks With Massive Wealth-Building Potential
Explore high-value stocks shaping the future across semiconductors, digital payments, AI, and healthcare for savvy investors. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Decoding Pfizer's Options Activity: What's the Big Picture?
Via Benzinga
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge
Legal actions surge against diabetes drug manufacturers Eli Lilly and Novo Nordisk. Patients allege severe complications, including gallbladder issues and gastroparesis, tied to GLP-1 agonists. Over 60... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Spinal Delivery Of Taysha's Gene Therapy Shows Promise In Rare Childhood Neurodegenerative Disease
Promising results from a Phase 1 trial led by NIH: scAAV9/JeT-GAN gene therapy shows potential benefits for giant axonal neuropathy. The therapy demonstrated safety and efficacy in children with GAN,... 
Via Benzinga
Is Cathie Wood Buying The Rumor? Ark More Than Doubles Stake In This COVID-19 Vaccine Maker Ahead Of Flurry Of Catalysts
Ark, through its flagship Ark Innovation ETF and Ark Genomic Revolution ETF, has been brisk with its acquisition of Moderna shares in March. 
Via Benzinga
Topics ETFs
Exposures COVID-19
EXCLUSIVE: Health Care Experts Discuss Critical Need For An Equitable System
Former Pfizer CMO Dr. Freda Lewis-Hall and ICR Westwicke's Michael O'Brien discuss challenges in autoimmune disease treatment and healthcare innovation. 
Via Benzinga
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials
BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine. 
Via Benzinga
Exposures COVID-19
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
BioNTech Tumbles As Fourth-Quarter Sales Dive 65% And Miss Forecasts
BioNTech also reported plummeting earnings that missed forecasts and issued light 2024 guidance. 
Via Investor's Business Daily
Why Is BioNTech Stock Trading Lower On Wednesday?
BioNTech reported Q4 2023 earnings below expectations, with EPS at €1.90 vs. €9.26 last year. Sales were €1.479 billion, missing consensus. Guidance for 2024 anticipates revenues of €2.5-€3.1 billion,... 
Via Benzinga
3 Juicy Stocks Serving Up 5% Dividends That You Can Snag for $50
These dividend stocks selling for under $50 with yields of 5% or more offer a lot to investors at any time making these strong buys. 
Via InvestorPlace
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon. 
Via Benzinga
7 Dangerous Dividend Stocks to Avoid at All Costs: March 2024
Lurking in the weeds like a tiger ready to strike, these dangerous dividend stocks are set to wreak havoc on any investment portfolio. 
Via InvestorPlace
5 Reasons Why Buying This 6%-Yielding Dividend Stock Could Be a Brilliant Move
Pfizer just might be one of the biggest comeback stories of the second half of this decade. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
These stocks could be cheap only for a season. 
Via The Motley Fool
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
Immuneering shares dip as analysts express concern over IMM-1-104 trial results. Needham downgrades, citing efficacy issues despite promising mechanism of action. Optimism remains for earlier-stage... 
Via Benzinga
3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise
Dive into the potential of precision medicine stocks poised to revolutionize healthcare and offer substantial growth opportunities. 
Via InvestorPlace
Is Pfizer Stock a Millionaire Maker?
A couple of years ago, Pfizer's shares may have seemed like a sure thing. That may not be the case anymore. 
Via The Motley Fool
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS